Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

57.1%

4 terminated/withdrawn out of 7 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

71%

5 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 3
5(71.4%)
Phase 2
2(28.6%)
7Total
Phase 3(5)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT03267108Phase 3Terminated

A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension

Role: lead

NCT01457781Phase 2Completed

Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)

Role: lead

NCT01728220Phase 2Completed

Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD

Role: lead

NCT04421508Phase 3Terminated

A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19

Role: lead

NCT02652429Phase 3Unknown

Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH

Role: lead

NCT03602781Phase 3Withdrawn

Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric

Role: lead

NCT02725372Phase 3Terminated

Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH

Role: lead

All 7 trials loaded